0
Products in the cart
Total:
Information block example
Currency
English Support
Request a call
Working hours:
Пн-Пт 9:00—23:00;
Сб-Вс 10:00-20:00

Rapacan 1mg

Rapacan 1mg (Sirolimus)

Rapacan 1mg lessen your body's immune system, to promote keep it from "deny" a transplanted organ such as a kidney.

Feature
Brand name:
Rapacan
Active substance:
Sirolimus 1mg
Manufacturer:
Biocon Ltd
Packaging:
10 Tablets
Product form:
Tablet
In stock
Active substance: Sirolimus
0 $
Available options:
Amount:
To wishlist
Compared
Consulting:+91(994)0472902
Description

DESCRIPTION

Rapacan 1mg lessen your body's immune system, to promote keep it from "deny" a transplanted organ such as a kidney. Organ deny happens when the immune system treats the new organ as a trespasser and attacks it.
Rapacan 1mg is also taken without other medicines to cure a rare lung disorder is known as lymphangioleiomyomatosis.
Rapacan 1mg which is used as prescription drug under guidance of medical practioners.

INDICATION

Rapacan 1mg tablets are prescribed for the prophylaxis of organ refusal in patients aged 13 years or older diagnosed renal transplants.

MECHANISM OF ACTION

Prevents T-cell activation and replication and prevents antibody production which results in response to antigenic and cytokine stimulation; blocking T- cell multiplication by prohibiting progression from the G1 to the S phase of the cell cycle.

Lymphangioleiomyomatosis contains lung tissue infiltration with smooth muscle-like cells which inlet quiet mutations of the tuberous sclerosis complex (TSC) gene (LAM cells)

Lack of TSC gene function stimulate the mTOR signaling pathway, reporting in cellular multiplication and release of lymphangiogenic growth factors

Sirolimus prohibits the activated mTOR pathway and thus the replication of LAM cells.

ADME PROPERTY

In healthy patients and renal transplant patients the high plasma concentration is 1-2 hours and bioavailability are 27%.
The drug has plasma protein binding is 92%
Rapacan is widely metabolized in the intestinal wall and liver. It is substrate for both CYP3A4 and P-gp
Most of radioactivity was recovered from the faces is 91% and only little amount was excreted in urine is 2.2%.
Half-life of Rapacan is 57-63 hours.

DOSAGE MANAGEMENT

RAPACAN IS USED FOR THE PROPHYLAXIS OF RENAL TRANSPLANT REJECTION :
Starting treatment combination with cyclosporine and corticosteroids

High immunologic risk
The prescribed loading dose is <40 kg: 3 mg/m² ≥40 kg: 15 mg PO loading dose Maintenance dose of Rapacan is 5 mg/day PO if >40 kg and 1 mg/m²/day if <40 kg on day 2 and after that; produce trough levels between days 5 and 7.
Dose should be adapting to maintain trough concentrations within desired range based on clinical state and combination therapy; further dose adjustment should not be done sooner than 7-14 days following a dose adjustment
Combination therapy: For the first year, continuing transplantation, Rapacan should be used in interaction with cyclosporine and corticosteroids; cyclosporine may be initiated at 7 mg/kg/day in double doses with the dose modify to get trough concentrations; prednisone should be taken at a dose of 5 mg/day
Low-to-moderate immunologic risk
The loading dose <40 kg: 3 mg/m² ≥40 kg: 6 mg PO loading dose Maintenance: 2 mg/day PO if ≥ 40 k g and 1 mg/m²/day if <40 kg on day 2 and thereafter; obtain trough levels between days 5 and 7
Dose should be adapting to maintain trough concentrations within desired range based on clinical state and combination therapy; further dose adjustment should not be done sooner than 7-14 days following a dose adjustment
Combination therapy: continuing transplantation, Rapacan should be used in interaction with cyclosporine and corticosteroids; may blocks cyclosporine gradually over 4-8 weeks two to four months after transplant in patients with less immunologic risk, &Rapacan dose higher (serum concentrations of sirolimus may reduce following cyclosporine withdrawal)
LYMPHANGIOLEIOMYOMATOSIS :
Rapacan indicated for treatment of lymphangioleiomyomatosis (LAM) Initial recommended dose: 2 mg/day PO given in 10-20 days and then monitor whole blood trough level
Over dosage :
If overdose occurs all should provide general supportive measures.

SIDE EFFECTS

Common side effects :
Fever, cold and cough
Mouth sores;
Nausea, stomach pain, diarrhoea;
Headache, muscle aches;
Chest pain;
Dizziness; or
Acne.
Other side effects, if it occurs then immediately call doctor :
Slow healing of a skin wound;
A new skin lesion,
Unusual bleeding
Sudden discomfort in chest, cough, feeling short of breath;
Pain around the transplanted kidney;
Infection like--fever, chills, painful mouth sores, skin sores, cold or flu symptoms, pain or burning when you urinate; or Anemia- skin in pale, unusual weakness, feeling light-headed or Dyspnea cold hands and feet.

PRECAUTION

Rapacan 1mg should be prescribed only by physicians who have experience with immunosuppression in organ transplant recipients and can supply necessary follow-up and appropriate checking
Do not use in liver or lung transplantation as safety and efficacy is not established
In liver transplant recipients have been noticed having high mortality, loss in graft, and hepatic artery thrombosis
In lung transplant recipients has been noticed Bronchial anastomotic dehiscence
Rapacan 1mg will have high risk of infection, lymphoma, and other malignancies due to raise immunosuppression
Greatest enhance sun exposure due to increased skin cancer risk
Patients generally presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia will have resulted Progressive multifocal leukoencephalopathy (PML), sometimes fatal

DRUG INTERACTION

Rapacan concomitant use with cyclosporine will increases sirolimus concentration. Hence sirolimus should give 4 hours after administration of cyclosporine

Avoid concomitant use of Rapacan with strong inducers and strong inhibitors will decrease interaction potential with sirolimus

Using with grapefruit juice will prevents the CY3A4 – mediated metabolism of Rapacan. Avoid during using with sirolimus

CONTRAINDICATION

hypersensitivity to sirolimus

PREGNANCY

Pregnancy category is C
Rapacan 1mg: There are no adequate and well-indulge studies in pregnant women. Active contraception must be started before sirolimus treatment, during sirolimus therapy, and for 12 weeks after Rapacan treatment has been stopped.

LACTATION

Many drugs are excreted in human milk, and because of the potential undesirable effects in nursing infants from Rapacan 1mg, a decision should be considered whether to halt for nursing or to discontinue the drug, considering the requirement of the drug to the mother.

STORAGE

Rapacan 1mg Stored at 20°C-25°C
Avoid using if blister is torn or broken.

MISSED DOSE

If dose is forget to take, have it soon before next dose reaches or skip the dose and follow normal timing
Please Consult with the doctor

Feature
Brand name
Rapacan
Active substance
Sirolimus 1mg
Manufacturer
Biocon Ltd
Packaging
10 Tablets
Product form
Tablet
Strength
1mg
Rapacan 1mg отзывы
Add a comment
0

We use cookies to make the site better for you! Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educati
MEDICAL DISCLAIMERAll the contents present on the website are solely for informational purposes. Thereby, the information on the website isn’t meant to be a substitute for professional medical advice, treatment, and/or diagnosis. Please seek professiona